Company

AbCellera Biologics Inc.

Headquarters: Vancouver, BC, Canada

Employees: 386

CEO: Dr. Carl L.G. Hansen Ph.D.

NASDAQ: ABCL -1.35%

Market Cap

$791.0 Million

USD as of July 1, 2024

Market Cap History

AbCellera Biologics Inc. market capitalization over time

Evolution of AbCellera Biologics Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of AbCellera Biologics Inc.

Detailed Description

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

AbCellera Biologics Inc. has the following listings and related stock indices.


Stock: NASDAQ: ABCL wb_incandescent

Stock: FSX: 8QQ wb_incandescent

Details

Headquarters:

2215 Yukon Street

Vancouver, BC V5Y 0A1

Canada

Phone: 604 559 9005